Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01280344 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function
A Phase 2 study of Gastrointestinal Dysmotility, sponsored by Helsinn Therapeutics (U.S.).
- Completed
- Registry status
- Phase 2
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT01280344: Completed Phase 2 study of Gastrointestinal Dysmotility, sponsored by Helsinn Therapeutics (U.S.).
NCT01280344 is a Phase 2 study of Gastrointestinal Dysmotility that has completed, run by Helsinn Therapeutics (U.S.). The registered enrollment target is 320 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (141% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01280344, a Phase 2 study of Gastrointestinal Dysmotility, has completed, sponsored by Helsinn Therapeutics (U.S.).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.
Primary Outcome
To assess the efficacy of three repeated dose levels of ipamorelin vs. placebo
Conditions Studied
Interventions
- DRUG Saline Solution for Injection
- DRUG Ipamorelin
Study Locations (20)
Florida
- - Aventura
- - Inverness
- - Miami
- - Orlando
- - Pensacola
- - Sarasota
- - Tampa
- - Weston
California
- - Fountain Valley
- - Glendale
- - Laguna Hills
- - Los Angeles
- - Orange
- - San Francisco
Alabama
- - Florence
- - Sheffield
Illinois
- - Chicago
- - Highland Park
Colorado
- - Aurora
Georgia
- - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
What the finished NCT01280344 record still lists
NCT01280344 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (141% higher).
The record links to 1 condition, with Gastrointestinal Dysmotility appearing as the primary indexed condition, and to 2 interventions - of which Saline Solution for Injection is the first listed.
NCT01280344 names 20 study sites across 6 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT01280344 about?
NCT01280344 is a clinical study titled "Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function". Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.
What is the current status of trial NCT01280344?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2011-04. Estimated completion is 2014-05.
What conditions does trial NCT01280344 study?
This clinical trial studies the following conditions: Gastrointestinal Dysmotility.
What interventions are being tested in trial NCT01280344?
The interventions under investigation include: Saline Solution for Injection (DRUG), Ipamorelin (DRUG).
Who is sponsoring clinical trial NCT01280344?
This trial is sponsored by Helsinn Therapeutics (U.S.), which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01280344 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Dysmotility
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01280344's enrollment target sits among peer trials
320 152nd of 2000 higher than 1,848 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia